EXO Biologics hopes to gain conditional marketing from Phase I/II BPD trial
EXO Biologics will be funding the Phase I/II trial with €16m ($17.1m) gained through Series A funding.
EXO Biologics will be funding the Phase I/II trial with €16m ($17.1m) gained through Series A funding.